Literature DB >> 30795693

Mepolizumab in adolescents with severe eosinophilic asthma not eligible for omalizumab: one center's early clinical experience.

Elise Weir1, James Paton2.   

Abstract

Entities:  

Year:  2019        PMID： 30795693     DOI： 10.1080/02770903.2019.1579833

Source DB:  PubMed          Journal:  J Asthma        ISSN： 0277-0903            Impact factor:   2.515


× No keyword cloud information.
  4 in total

Review 1.  Resolution of allergic asthma.

Authors:  Susetta Finotto
Journal:  Semin Immunopathol       Date:  2019-11-08       Impact factor: 9.623

2.  Resolution of inflammation: from basic concepts to clinical application.

Authors:  Markus F Neurath
Journal:  Semin Immunopathol       Date:  2019-11       Impact factor: 9.623

Review 3.  Novel therapeutic targets for allergic airway disease in children.

Authors:  Alessandro Giallongo; Giuseppe Fabio Parisi; Amelia Licari; Giulio Pulvirenti; Caterina Cuppari; Carmelo Salpietro; Gian Luigi Marseglia; Salvatore Leonardi
Journal:  Drugs Context       Date:  2019-07-09

4.  Viral etiology and atopic characteristics in high-risk asthmatic children hospitalized for lower respiratory tract infection.

Authors:  Ting Wang; Heting Dong; Wujun Jiang; Yan Li; Huiming Sun; Li Huang; Meijuan Wang; Canhong Zhu; Wei Ji; Yuqing Wang; Chuangli Hao; Zhengrong Chen; Yongdong Yan
Journal:  Transl Pediatr       Date:  2020-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.